Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide plus TGA chemotherapy for relapsed or refractory pediatric yolk sac tumor
ChiCTR2200061195Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in yolk sac tumor, sponsored by Shandong Cancer Hospital. Primary endpoint: Medical images. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
thalidomide
03
Conditions
yolk sac tumor
Beyond the preview
Go deeper on ChiCTR2200061195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061195.